NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
Total of $122.5M Series B funding includes $42.5M Extension from new and existing investors Financing propels company to transform the potential of immunotherapy into precision oncology by leveraging HHLA2/B7-H7 for both immunomodulation and direct tumor-targeting…